Valiant Laboratories Limited

BSE: 543998 NSE: VALIANTLAB
Valiant Laboratories Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24299MH2021PLC365904 Incorporated 16 August 2021 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: VALIANTLAB · BSE: 543998 Public Limited Company pharma
Data last updated
Market Cap
₹697 Cr
VALIANTLAB · NSE
Share Price
₹128.40
+0.05% today
Revenue
₹237 Cr
FY 2025-26 · +78.0% YoY
EBITDA
₹6.39 Cr
Margin 2.7%
Net Profit
−₹3.27 Cr
FY 2025-26 · +3.3% YoY
P/E (TTM)
42.7x
P/B 2.2x
Authorised capital
₹60 Cr
Registered with MCA
Paid-up capital
₹54.31 Cr
Issued & subscribed

About Valiant Laboratories Limited

Data last updated:

Valiant Laboratories Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 16 August 2021 and has been in existence for over 5 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24299MH2021PLC365904. Its GSTIN is 27AAICV2239F1ZA (Maharashtra). It is a listed company as per MCA records. Its shares are listed on BSE: 543998 and NSE: VALIANTLAB.

The company has an authorised share capital of ₹60 Cr and a paid-up capital of ₹54.31 Cr. It is led by directors including Santosh Shantilal Vora (Managing Director) and Paresh Shashikant Shah (Whole-Time Director).

Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 104 Udyog Kshetra Mulundgoregoanlinkroad Mulund West, Mumbai, Maharashtra, India – 400080.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹237.47 Cr, a growth of 78% compared to the previous year. For the same year it recorded a net loss of ₹3.27 Cr (net margin -1.4%) and EBITDA of ₹6.39 Cr (EBITDA margin 2.7%).

The company has about 77 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Valiant Laboratories. As per MCA filings, the company has open charges of ₹60.86 Cr and satisfied charges of ₹52 Cr on record. Court records list 1 case involving the company, including 1 filed by the company; 1 case is pending. The company has 11 deals on record (9 market trades, 1 rights issue, 1 ipo); the latest was in December 2025. Its 9 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is R.L.Fine Chem Private Limited with revenue of ₹360.48 Cr. The company has 4 MSME Form 1 returns on record for the period ending Sep 2023, listing 16 overdue payments to 7 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website valiantlabs.in.

Company details

CIN L24299MH2021PLC365904
Registration Number 365904
Incorporation Date 16 August 2021
ROC Mumbai
Listing Status Listed - Listed on NSE (VALIANTLAB); Listed on BSE (543998)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Valiant Laboratories has one previous CIN (Corporate Identification Number): U24299MH2021PLC365904. The current CIN is L24299MH2021PLC365904, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24299MH2021PLC365904Current
U24299MH2021PLC365904Previous
Key People
Santosh Shantilal Vora Managing Director Paresh Shashikant Shah Whole-Time Director Shantilal Shivji Vora Director

Contact details

Valiant Laboratories Limited's registered office is in Mumbai, Maharashtra. Its website is valiantlabs.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    valiantlabs.in
  • Registered Address
    104 Udyog Kshetra Mulundgoregoanlinkroad Mulund West, Mumbai, Maharashtra, India – 400080
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Valiant Laboratories Limited, buy the company report.

Comprehensive company report
Valiant Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Valiant Laboratories operates one associated brand: Valiant Laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Valiant Laboratories
Valiant Laboratories is engaged in manufacturing active pharmaceutical ingredients.valiantlabs.in

Business activity

The main business activity of Valiant Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Valiant Laboratories Limited, buy the company report.

Financials of Valiant Laboratories Limited

FY 2025-26 filings available

Valiant Laboratories Limited reported revenue of ₹237.47 Cr (up 78% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹237 Cr
+78.0% YoY
EBITDA
₹6.39 Cr
+236.2% YoY
Profit After Tax
−₹3.27 Cr
+3.3% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue237133182334
Revenue growth+78.0%-26.7%-45.5%-
EBITDA6.39(4.69)(8.40)35.10
EBITDA margin+2.7%-3.5%-4.6%+10.5%
Profit before tax0.77(1.53)(0.77)38.15
Net profit(3.27)(3.38)(2.88)29.01
Net profit margin-1.4%-2.5%-1.6%+8.7%
EPS (₹)(0.51)(0.51)0.078.91
Balance sheet
Total assets-357315162
Net worth-234237100
Total debt-12276.7160.22
Cash & bank-75.991061.34
Net working capital-15016066.01
Cash flow
Cash from operations-1.311.8956.05
Cash from investing-(52.77)(144)(55.17)
Cash from financing-44.65152(0.93)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue11591.9852.4646.2046.8257.7935.2321.48
Revenue growth (YoY)+146.2%+59.2%+48.9%+115.1%+148.0%---
Other income0.860.170.630.870.66(2.31)1.583.36
EBITDA29.264.81(0.89)0.082.403.830.62(6.74)
EBITDA margin+25.4%+5.2%-1.7%+0.2%+5.1%+6.6%+1.8%-31.4%
Depreciation2.862.932.050.530.530.520.520.52
Interest1.071.010.680.140.070.050.060.01
Profit before tax26.191.04(2.99)0.282.460.951.62(3.91)
Tax5.09(0.71)4.070.070.630.24(0.72)0.83
Net profit21.101.75(7.06)0.211.830.712.34(4.74)
EPS (₹)3.890.35(1.30)0.040.420.160.54(1.09)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue217133182334292182
Revenue growth+62.8%-26.8%-45.5%+14.5%+59.9%-
EBITDA7.17(4.68)(8.40)35.0942.3150.00
EBITDA margin+3.3%-3.5%-4.6%+10.5%+14.5%+27.4%
Profit before tax7.54(1.45)(0.75)38.1441.7047.02
Net profit5.54(3.31)(2.86)29.0027.4630.59
Net profit margin+2.6%-2.5%-1.6%+8.7%+9.4%+16.8%
EPS (₹)1.10(0.49)0.088.9116.8929.14
Balance sheet
Total assets-29529816213490.15
Net worth-23423710071.4688.58
Total debt-59.8860.0660.2261.130.60
Cash & bank-27.3496.720.4620.1318.94
Net working capital-98.5114697.6010870.27
Cash flow
Cash from operations-(21.90)48.7822.962.259.11
Cash from investing-24.97(183)(21.18)(12.24)(16.67)
Cash from financing-(0.50)136(1.53)6.1811.43
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue73.4265.3054.7445.9951.0157.7735.2321.48
Revenue growth (YoY)+43.9%+13.0%+55.4%+114.1%+170.2%---
Other income0.850.770.610.850.670.650.671.93
Total expenses60.9260.8054.4945.9348.6553.9434.6028.22
EBITDA12.504.500.250.062.363.830.63(6.74)
EBITDA margin+17.0%+6.9%+0.5%+0.1%+4.6%+6.6%+1.8%-31.4%
Depreciation0.550.520.720.510.510.510.510.51
Interest0.080.020.030.140.070.050.060.01
Profit before tax12.724.730.110.262.453.920.73(5.33)
Tax3.251.200.080.090.630.69(0.88)0.66

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 31 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue11591.9852.4646.2046.8257.7935.2321.48
Revenue growth (YoY)+146.2%+59.2%+48.9%+115.1%+148.0%---
Other income0.860.170.630.870.66(2.31)1.583.36
EBITDA29.264.81(0.89)0.082.403.830.62(6.74)
EBITDA margin+25.4%+5.2%-1.7%+0.2%+5.1%+6.6%+1.8%-31.4%
Depreciation2.862.932.050.530.530.520.520.52
Interest1.071.010.680.140.070.050.060.01
Profit before tax26.191.04(2.99)0.282.460.951.62(3.91)
Tax5.09(0.71)4.070.070.630.24(0.72)0.83
Net profit21.101.75(7.06)0.211.830.712.34(4.74)
EPS (₹)3.890.35(1.30)0.040.420.160.54(1.09)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue237133182334
Revenue growth+78.0%-26.7%-45.5%-
Other income2.325.439.684.86
Total expenses231138190299
Employee cost0.004.394.314.61
EBITDA6.39(4.69)(8.40)35.10
EBITDA margin+2.7%-3.5%-4.6%+10.5%
Depreciation6.042.091.971.56
Interest1.900.180.080.25
Profit before tax0.77(1.53)(0.77)38.15
Tax4.040.69(1.09)9.14
Net profit(3.27)(3.38)(2.88)29.01
Net profit margin-1.4%-2.5%-1.6%+8.7%
EPS (₹)(0.51)(0.51)0.078.91
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital-43.4543.4532.56
Reserves & surplus-19119367.93
Shareholders' funds (net worth)-234237100
Minority interest-0.000.000.00
Secured loans-61.8016.650.00
Unsecured loans-59.8860.0660.22
Total debt-12276.7160.22
Total liabilities-357315162
Assets
Gross block-70.6770.2166.31
Net block-48.4450.0548.12
Capital work in progress-15642.650.68
Investments-0.0037.6134.02
Inventories-3.9910.0213.04
Sundry debtors-72.1245.7388.57
Cash & bank balances-75.991061.34
Loans & advances-40.5225.9813.61
Total current assets-193188117
Total current liabilities-42.5327.4650.55
Net working capital-15016066.01
Total assets-357315162
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash-11.721.261.31
Net cash from operating activities-1.311.8956.05
Net cash from investing activities-(52.77)(144)(55.17)
Net cash from financing activities-44.65152(0.93)
Net change in cash-(6.80)10.46(0.05)
Closing cash-75.991061.34
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+78.0%-26.7%-45.5%-
EBITDA growth+236.3%+44.2%-123.9%-
PBT growth+9998.0%-98.7%-+9997.0%
Net income growth+3.3%-17.4%-109.9%-
Revenue CAGR (3Y)-10.7%---
EBITDA CAGR (3Y)-43.3%---
Profitability & leverage
Net income margin-1.4%-1.7%+0.2%+8.7%
Return on capital employed--1.0%-1.6%+23.7%
Return on net worth--1.4%-1.7%+28.9%
Debt / equity-0.420.410.60
Long-term debt / equity-0.380.400.60
Interest cover542.86-2.65-0.770.75
Efficiency & per share
Fixed asset turnover-1.892.675.04
Inventory turnover-19.0415.7925.61
Debtors turnover-2.262.713.77
EPS (₹)(0.51)(0.51)0.078.91
Dividend per share (₹)0.000.000.000.00
Book value per share (₹)0.0053.9354.5130.86
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue73.4265.3054.7445.9951.0157.7735.2321.48
Revenue growth (YoY)+43.9%+13.0%+55.4%+114.1%+170.2%---
Other income0.850.770.610.850.670.650.671.93
Total expenses60.9260.8054.4945.9348.6553.9434.6028.22
EBITDA12.504.500.250.062.363.830.63(6.74)
EBITDA margin+17.0%+6.9%+0.5%+0.1%+4.6%+6.6%+1.8%-31.4%
Depreciation0.550.520.720.510.510.510.510.51
Interest0.080.020.030.140.070.050.060.01
Profit before tax12.724.730.110.262.453.920.73(5.33)
Tax3.251.200.080.090.630.69(0.88)0.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue217133182334292182
Revenue growth+62.8%-26.8%-45.5%+14.5%+59.9%-
Other income2.895.439.684.861.951.41
Total expenses210138190299249132
Employee cost0.004.394.314.613.062.71
EBITDA7.17(4.68)(8.40)35.0942.3150.00
EBITDA margin+3.3%-3.5%-4.6%+10.5%+14.5%+27.4%
Depreciation2.262.021.951.562.492.61
Interest0.260.180.080.250.071.78
Profit before tax7.54(1.45)(0.75)38.1441.7047.02
Tax2.000.71(1.09)9.1414.2116.43
Net profit5.54(3.31)(2.86)29.0027.4630.59
Net profit margin+2.6%-2.5%-1.6%+8.7%+9.4%+16.8%
EPS (₹)1.10(0.49)0.088.9116.8929.14
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital-43.4543.4532.5616.2810.50
Reserves & surplus-19119367.9355.1878.08
Shareholders' funds (net worth)-23423710071.4688.58
Secured loans-59.4059.4059.401.280.35
Unsecured loans-0.480.660.8259.850.25
Total debt-59.8860.0660.2261.130.60
Total liabilities-29529816213490.15
Assets
Gross block-42.7742.3538.7629.7525.12
Net block-30.0231.6129.9722.2219.79
Capital work in progress-0.170.220.051.450.00
Investments-16511934.030.400.00
Inventories-3.9610.0213.0415.806.07
Sundry debtors-72.1045.7288.5711142.51
Cash & bank balances-27.3496.720.4620.1318.94
Loans & advances-15.8319.2045.889.6918.37
Total current assets-11917214815685.89
Total current liabilities-20.7226.1450.3547.9715.62
Net working capital-98.5114697.6010870.27
Total assets-29529816213490.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash-2.230.380.133.940.07
Net cash from operating activities-(21.90)48.7822.962.259.11
Net cash from investing activities-24.97(183)(21.18)(12.24)(16.67)
Net cash from financing activities-(0.50)136(1.53)6.1811.43
Net change in cash-2.571.850.24(3.81)3.87
Closing cash-27.3496.720.4620.1318.94
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+62.8%-26.8%-45.5%+14.5%+59.9%-
EBITDA growth+253.2%+44.3%-123.9%-17.1%-15.4%-
PBT growth+9998.0%-93.3%--8.5%-11.3%+9997.0%
Net income growth+267.4%-15.7%-109.9%+5.6%-10.2%-
Revenue CAGR (3Y)-13.4%-23.0%-0.1%---
EBITDA CAGR (3Y)-41.1%-----
Profitability & leverage
Net income margin+2.6%-1.6%+0.2%+8.7%+9.4%+16.8%
Return on capital employed--1.1%-1.7%+26.0%+37.4%+54.1%
Return on net worth--1.4%-1.7%+33.7%+34.4%+34.5%
Debt / equity-0.250.360.710.390.01
Long-term debt / equity-0.250.360.700.370.00
Interest cover5.30-2.69-0.770.750.183.76
Efficiency & per share
Fixed asset turnover-3.134.499.7510.637.26
Inventory turnover-19.0815.7923.1626.6630.04
Debtors turnover-2.262.713.353.804.29
EPS (₹)1.10(0.49)0.088.9116.8929.14
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)0.0053.9454.5230.8643.8984.36

To see the full year-wise statements and ratios of Valiant Laboratories Limited, buy the company report.

Board of directors of Valiant Laboratories Limited

Valiant Laboratories has 7 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Santosh Shantilal Vora
Also directs: Valiant Organics Limited, Valiant Advanced Sciences Private Limited
Managing Director16 Aug 20215 Years 2 MonthsCurrent
Shantilal Shivji VoraDirector16 Aug 20215 Years 2 MonthsCurrent
Paresh Shashikant Shah
Also directs: Valiant Advanced Sciences Private Limited, Empeef Chemicals Pvt Ltd
Whole-Time Director16 Aug 20215 Years 2 MonthsCurrent
Sonal Amit Vira
Also directs: Valiant Organics Limited, Valiant Advanced Sciences Private Limited
Director16 Feb 20224 Years 8 MonthsCurrent
Sandeep Gupta
Also directs: Alchemie Finechem Private Limited
Director23 Feb 20233 Years 8 MonthsCurrent
Ashok Lakhamshi Chheda
Also directs: Stature Realtor Private Limited
Director12 Nov 20241 Years 11 MonthsCurrent
Showing 6 of 7 current directors. View all directors

Peer comparison

Valiant Laboratories Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
R.L.Fine Chem Private Limited₹360.48 Cr (FY 2025)6.0%Bangalore, Karnataka, India
Vital Laboratories Private Limited₹357.13 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Haleos Labs Limited₹349.58 Cr (FY 2025)13.0%Hyderabad, Telangana, India
SCL Lifesciences Limited₹340.47 Cr (FY 2025)-4.0%Punjab, India
Mehta Api Private Limited₹325.77 Cr (FY 2025)36.0%Mumbai, Maharashtra, India
Synergene Active Ingredients Private Limited₹319.93 Cr (FY 2024)37.0%Hyderabad, Telangana, India
Mangalam Drugs and Organics Limited₹318.73 Cr (FY 2025)-14.0%Mumbai, Maharashtra, India
Saraca Laboratories Limited₹310.45 Cr (FY 2025)11.0%Hyderabad, Telangana, India
Megafine Pharma Private Limited₹310.01 Cr (FY 2025)-5.0%Mumbai, Maharashtra, India
Valiant Laboratories Limitedthis company₹237.47 Cr (FY 2026)-₹3.27 Cr-1.4%78.0%77Mumbai, Maharashtra, India

To see the full peer comparison of Valiant Laboratories Limited, buy the company report.

Auditor

Valiant Laboratories Limited is audited by Raman S Shah & Co for the financial year 2023.

Auditor firmFinancial yearFirm registration number
Raman S Shah & CoFY 2023111919W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 74.90%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 25.10%.

Promoters: 74.90%Retail & Others: 25.10%
Sep 2026
QUARTER
74.90% Promoters
25.10% Retail & Others
Promoter holding - history
Now 74.90% · Sep 2026High 74.90% · Dec 2025Low 74.90% · Dec 2025
73%73.8%74.5%75.3%76%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 74.90%Mar 2026: 74.90%Jun 2026: 74.90%Sep 2026: 74.90%74.90%74.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters74.90%74.90%74.90%74.90%
Public25.10%25.10%25.10%25.10%

Charges & borrowings

Open charges
₹60.86 Cr
Satisfied charges
₹52 Cr
Breakdown by lending institutions
Others₹52.00 Cr
The Hongkong and Shanghai Banking Corporation Limited₹8.86 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
29 May 2025101111471The Hongkong and Shanghai Banking Corporation Limited₹1 CrOpen
08 Jun 2024100937463The Hongkong and Shanghai Banking Corporation Limited₹2.86 CrOpen
28 Feb 2024100874834The Hongkong and Shanghai Banking Corporation Limited₹5 CrOpen
23 Sep 2022100617061Others₹52 CrOpen
14 Oct 2022100622621Others₹52 CrSatisfied

To see the full charge records of Valiant Laboratories Limited, buy the company report.

Total charge records: 5 View all charges

Deals & funding

Valiant Laboratories Limited has 11 deals on record (9 market trades, 1 rights issue, 1 ipo); the latest was in December 2025.

Total deals
11
Market trades
9
Rights issue
1
IPO
1

Deals on record (5 of 11)

WhenDealAmountParties
Jan 2025Market trade₹2.83 CrBuyer: an individual
Seller: Marwadi Chandarana Intermediaries Brokers Private Limited
Jan 2025Market trade₹5.82 CrBuyer: Money Logix Securities Private Limited
Seller: Jainam Broking Limited
Jun 2024Market trade₹5.17 CrBuyer: Jainam Broking Limited , an individual
Seller: Jainam Broking Limited
Jan 2024Market trade₹4.34 CrBuyer: Anant Wealth Consultants Private Limited
Seller: Anant Wealth Consultants Private Limited
Oct 2023Market trade₹19.45 CrBuyer: 2 individuals
Seller: Alpha Alternatives Msar LLP , Alpha Alternatives Financial Services Private Limited

To see the full deal history of Valiant Laboratories Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Valiant Laboratories Limited has 4 MSME Form 1 returns on record for the period ending Sep 2023, listing 16 overdue payments to 7 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 7)

SupplierAmount dueDue sinceReported on
Hesaone LLP
MRJ Apparels
an individual supplier
an individual supplier
an individual supplier

To see the full MSME payment records of Valiant Laboratories Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Valiant Laboratories has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Valiant Advanced Sciences Private LimitedU24290MH2022PTC386388

To see the full group structure of Valiant Laboratories Limited, buy the company report.

Employees & EPFO

Valiant Laboratories Limited has a workforce of 77 employees on its EPFO records as of Apr 08, 2025, across 1 active EPFO establishment.

Employee count
77
Active EPFO establishments
1
Employee growth
-7.23%

GST

Valiant Laboratories has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27AAICV2239F1ZAMaharashtraActive16 Aug 2021

To see the full GST registrations and return filing status of Valiant Laboratories Limited, buy the company report.

Recent activity

Valiant Laboratories Limited has 9 board changes on record since 2021: 8 appointments and 1 cessation. The latest: Ashok Lakhamshi Chheda was appointed as Director on 12 Nov 2024.

Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited of Rs. 2.86 Cr registered on 08 Jun 2024 with Charge ID 100937463 was modified on 27 Apr 2026.
Filing
Valiant Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Valiant Laboratories Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Charges
A charge with Others of Rs. 52.00 Cr registered on 23 Sep 2022 with Charge ID 100617061 was modified on 04 Sep 2025.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 1.00 Cr with Charge ID 101111471 was registered on 29 May 2025.
Appointed
Ashok Lakhamshi Chheda was appointed as Director.
Ceased
Velji Karamshi Gogri ceased to be Director.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 2.86 Cr with Charge ID 100937463 was registered on 08 Jun 2024.
Appointed
Mulesh Manilal Savla was appointed as Director.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 5.00 Cr with Charge ID 100874834 was registered on 28 Feb 2024.
Charges
A charge registered on 14 Oct 2022 via Charge ID 100622621 with Others was fully satisfied on 14 Aug 2023.
Appointed
Sandeep Gupta was appointed as Director.

8 earlier events are in the company report.

News

Frequently asked questions

Valiant Laboratories is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 16 August 2021 (5+ years old) and is registered under CIN L24299MH2021PLC365904. Listed on BSE: 543998 and NSE: VALIANTLAB.

Valiant Laboratories reported revenue of ₹237.47 Cr for FY 2025-26 (up 78% YoY) based on consolidated financials.

Valiant Laboratories has 7 current directors:

The latest financial statements of Valiant Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from FY 2022 are in the company report.

The GSTIN of Valiant Laboratories is 27AAICV2239F1ZA, registered in Maharashtra.

The CIN (Corporate Identification Number) of Valiant Laboratories is L24299MH2021PLC365904. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Valiant Laboratories is a listed company as per MCA records. Its shares are listed on both BSE (code: 543998) and NSE (symbol: VALIANTLAB).

Valiant Laboratories has 1 court case on record: 1 filed by the company. 1 is pending.

Valiant Laboratories was incorporated on 16 August 2021, making it 5+ years old. It is registered with the Registrar of Companies, Mumbai.

Valiant Laboratories has 11 deals on record (9 market trades, 1 rights issue, 1 ipo); the latest was in December 2025.

The peers of Valiant Laboratories by revenue are R.L.Fine Chem Private Limited, Vital Laboratories Private Limited, Haleos Labs Limited, SCL Lifesciences Limited, Mehta Api Private Limited and 4 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Ashok Lakhamshi Chheda was appointed as Director on 12 Nov 2024. Velji Karamshi Gogri ceased to be Director on 12 Nov 2024. Mulesh Manilal Savla was appointed as Director on 14 May 2024. Valiant Laboratories has 9 board changes on record in total.